» Articles » PMID: 34870059

Dopamine-Secreting Pheochromocytoma and Paraganglioma

Overview
Journal J Endocr Soc
Specialty Endocrinology
Date 2021 Dec 6
PMID 34870059
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Predominantly or exclusively dopamine-secreting pheochromocytoma and paraganglioma are very rare. We report a 64-year-old woman with an adrenal incidentaloma. She was normotensive and had no symptoms of catecholamine excess. The 24-hour urine catecholamine level showed normal norepinephrine (122.9 μg/day), normal epinephrine (24.3 μg/day), and markedly elevated dopamine (148 212.4 μg/day). I-metaiodobenzylguanidine (MIBG) scintigraphy revealed tumor uptake. After α-blockade as preoperative management, she successfully underwent laparoscopic left adrenalectomy and was finally diagnosed with an exclusively dopamine-secreting pheochromocytoma. The tumor was histologically comprised of small polygonal cells with high cellularity and was immunohistochemically positive for all 3 catecholamine-synthesizing enzymes: tyrosine hydroxylase (very weak), dopamine β-hydroxylase (heterogeneous), and phenylethanolamine N-methyltransferase (very weak). Electron microscopy revealed very few catecholamine-containing small vesicles with a few organelles, which reflected immature cells. No biochemical or imaging evidence of recurrence or metastasis were evident 1 year after the surgery. We conducted a literature search in the PubMed database. A total of 33 cases were collected. Our case had the second-highest 24-hour urinary dopamine excretion and was the first in which immunostaining for catecholamine synthase and electron microscopy were performed together. Histological findings in our case give a possible hypothesis that the mechanism underlying a dopamine-secreting pheochromocytoma is associated with immature catecholamine vesicles in which dopamine β-hydroxylase is localized, thus resulting in inhibited conversion from dopamine to norepinephrine. We also discuss the reasons for the lack of catecholamine excess symptoms, whether preoperative management of α-blockade is needed, and the association between the prognosis and genetic mutation, with an extensive literature review.

Citing Articles

Metastatic Pheochromocytoma/Paraganglioma Overproducing Multiple Catecholamines.

Yoshioka K, Nakano Y, Horichi M, Aono D, Takeshita Y, Takamura T JCEM Case Rep. 2024; 3(1):luae241.

PMID: 39726667 PMC: 11669864. DOI: 10.1210/jcemcr/luae241.


Nanoplasmonic aptasensor for sensitive, selective, and real-time detection of dopamine from unprocessed whole blood.

Biswas A, Lee S, Cencillo-Abad P, Karmakar M, Patel J, Soudi M Sci Adv. 2024; 10(36):eadp7460.

PMID: 39231221 PMC: 11373595. DOI: 10.1126/sciadv.adp7460.


Dopamine-Secreting Carotid Body Paraganglioma in a Patient With SDHB Mutation.

Mustafa K, Zadeh S, Culver S AACE Clin Case Rep. 2024; 10(3):109-112.

PMID: 38799041 PMC: 11127581. DOI: 10.1016/j.aace.2024.03.003.


Jugular Foramen Paragangliomas.

Ceccato G, Borba L Adv Tech Stand Neurosurg. 2024; 49:201-229.

PMID: 38700686 DOI: 10.1007/978-3-031-42398-7_10.


Massive Biochemically Silent Pheochromocytoma Masquerading as Nonfunctioning Adrenocortical Cancer.

Kumar S, Wu K, Rodrigo N, Glover A JCEM Case Rep. 2023; 1(3):luad061.

PMID: 37908587 PMC: 10580479. DOI: 10.1210/jcemcr/luad061.


References
1.
Wassenberg T, Deinum J, van Ittersum F, Kamsteeg E, Pennings M, Verbeek M . Clinical presentation and long-term follow-up of dopamine beta hydroxylase deficiency. J Inherit Metab Dis. 2020; 44(3):554-565. PMC: 8246878. DOI: 10.1002/jimd.12321. View

2.
Eisenhofer G, Goldstein D, Sullivan P, Csako G, Brouwers F, Lai E . Biochemical and clinical manifestations of dopamine-producing paragangliomas: utility of plasma methoxytyramine. J Clin Endocrinol Metab. 2005; 90(4):2068-75. DOI: 10.1210/jc.2004-2025. View

3.
Yi J, Oh E, Lee K, Choi J, Hoon Koo D, Kim K . An exclusively dopamine secreting paraganglioma in the retroperitoneum: a first clinical case in Korea. J Korean Surg Soc. 2012; 82(6):389-93. PMC: 3373991. DOI: 10.4174/jkss.2012.82.6.389. View

4.
Foo S, Chan S, Ananda V, Rajasingam V . Dopamine-secreting phaeochromocytomas and paragangliomas: clinical features and management. Singapore Med J. 2010; 51(5):e89-93. View

5.
Feldman J, Blalock J, Zern R, Shelburne J, Gaede J, Farrell R . Deficiency of dopamine-beta-hydroxylase. A new mechanism for normotensive pheochromocytomas. Am J Clin Pathol. 1979; 72(2):175-85. DOI: 10.1093/ajcp/72.2.175. View